hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06305910 id: CMN-DMGVac-01 briefTitle: CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults overallStatus: RECRUITING date: 2024-03-15 date: 2025-09-15 date: 2027-01-15 date: 2024-03-12 date: 2024-03-12 name: OX2 Therapeutics class: INDUSTRY briefSummary: This is a single center Phase I study of a new adjuvant CD200 activation receptor ligand, CD200AR-L, in combination with imiquimod and GBM6-AD vaccine to treat malignant glioma in children and young adults.
The primary objective of this study is to determine the maximum tolerated dose (MTD) of CD200AR-L when given with a fixed dose of GBM6-AD vaccine, imiquimod, and a single dose of radiation for patients with recurrent High Grade Glioma (HGG) or following standard of care therapy radiation therapy for newly diagnosed Newly Diagnosed Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma (DIPG/DMG). conditions: Diffuse Midline Glioma, H3 K27M-Mutant conditions: Recurrent High Grade Glioma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL interventionModelDescription: 3+3 design primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Treatment with CD200AR-L measure: Maximum Tolerated Dose (MTD) of CD200AR-L measure: Incidence of serious adverse events (SAEs) measure: Time to progression (TTP) by 24 months measure: Progression free survival (PFS) by 24 months measure: Overall survival (OS) by 24 months sex: ALL minimumAge: 2 Years maximumAge: 25 Years stdAges: CHILD stdAges: ADULT facility: Children's Minnesota status: RECRUITING city: Minneapolis state: Minnesota zip: 55404 country: United States name: Anne Bendel, MD role: CONTACT phone: 612-813-5940 email: anne.bendel@childrensmn.org lat: 44.97997 lon: -93.26384 hasResults: False
nctId: NCT06305897 id: CS5_10B briefTitle: Evaluation of the Tolerance (Main Objective) and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post-inflammatory Hyperpigmentation) on the Face acronym: CS5_10B overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12 date: 2024-12 date: 2024-03-12 date: 2024-04-17 name: Cryonove Pharma class: INDUSTRY briefSummary: The goal of this clinical trial is to compare the 3 different prototype of cyto-selective cryotherapy devices (name of the devices : CRYONOVE) use in brown spots on the face of subject from different ethnicities. The main questions it aims to answer are:
Researchers will compare the tolerance and performance of the 3 prototypes. conditions: Lentigo conditions: Solar Lentigo conditions: Post Inflammatory Hyperpigmentation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Proof of concept study concerning 3 prototypes of cyto-selective cryotherapy devices corresponding to a modified CE marked medical device (ref: 822-v1). primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 45 type: ESTIMATED name: CRYONOVE (EC14_4osc) name: CRYONOVE (EC+05_1osc) name: CRYONOVE (EC+05_2osc) measure: Tolerance measure: Performance sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06305884 id: OSU-21287 id: NCI-2023-03077 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) briefTitle: Transcutaneous Sensors for the Detection of Cancer-Related Lymphedema, Project Limb Rescue Study overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-12-31 date: 2025-12-31 date: 2024-03-12 date: 2024-03-12 name: Ohio State University Comprehensive Cancer Center class: OTHER briefSummary: This clinical trial studies how well new adhesive-based sensors that stick to the skin (transcutaneous) work in detecting cancer-related long-term arm swelling (lymphedema). For many patients, lymphedema s painful, unsightly, and weakening. The early signs of lymphedema are hard to see, and sometimes it is only diagnosed by hospital equipment at larger centers. Treating lymphedema early is usually more successful than trying to treat in later stages. The adhesive-based sensors used in this study work by using techniques called photoplethysmography (PPG) and bioimpedance (BI). PPG is an optical technique that can be used to detect blood volume changes in tissue. BI evaluates how tissue responds to an externally applied electrical current. This study may assist researchers in distinguishing participants with lymphedema in comparison to participants without lymphedema, and develop a way for patients to check for lymphedema at home. conditions: Hematopoietic and Lymphoid System Neoplasm conditions: Lymphedema conditions: Malignant Solid Neoplasm studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 70 type: ESTIMATED name: Bioelectric Impedance Analysis name: Exercise name: Photoplethysmography name: Questionnaire Administration measure: Unique signature describing photoplethysmography and bioimpedance at rest and during activity measure: Patient reported outcomes measure: Tolerability of sensors measure: Likely classification for lymphedema sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ohio State University Comprehensive Cancer Center city: Columbus state: Ohio zip: 43210 country: United States name: Carlo M. Contreras, MD role: CONTACT phone: 614-293-3465 email: Carlo.Contreras@osumc.edu name: Carlo M. Contreras, MD role: PRINCIPAL_INVESTIGATOR lat: 39.96118 lon: -82.99879 hasResults: False
nctId: NCT06305871 id: 2023-NHLHCRF-YYPPLC-ZR-09 briefTitle: Clinical Study of Ultrasound-guided Radiofrequency Ablation in the Treatment of Refractory Hyperthyroidism overallStatus: ACTIVE_NOT_RECRUITING date: 2023-08-01 date: 2025-07-31 date: 2025-07-31 date: 2024-03-12 date: 2024-03-12 name: Zhang Bo class: OTHER briefSummary: Hyperthyroidism is an endocrine disease with a high incidence rate, and some patients are difficult to effectively control the condition after long-term drug treatment, and the disease recurs, forming refractory hyperthyroidism. The search for a new safe, effective and minimally invasive treatment has become a research hotspot. Ultrasound-guided radiofrequency ablation is a hot spot in clinical research due to its advantages of low trauma, high safety, precise inactivation of lesions, and multiple ablation. However, there is no unified standard for the number and scope of ablation in the treatment of refractory hyperthyroidism by radiofrequency ablation, and there is a lack of data on the effectiveness and safety of the treatment with large samples and long-term effects. Therefore, how to establish a standardized treatment strategy and appropriate plan for ablation of refractory hyperthyroidism based on clinical practice is an urgent problem to be solved. The purpose of this study was to prospectively include refractory hyperthyroidism for ultrasound-guided radiofrequency ablation, and to evaluate the efficacy and safety of hyperthyroidism ablation by comparing the changes in symptoms and signs, serology, and imaging of patients before and after ablation. The relevant factors affecting the efficacy of ablation were analyzed and the most appropriate ablation scope was determined. Radiofrequency ablation was retrospectively compared with traditional surgery and 131I treatment, and the near- and medium-term treatment effects, incidence of adverse reactions and complications, as well as the economic benefits and sociopsychological differences of the three treatment methods were compared.
The expected outcome of this study is to establish a research cohort of hyperthyroidism ablation based on a large sample population, and to establish the most appropriate and effective regimen for radiofrequency ablation of refractory hyperthyroidism compared with traditional surgery and 131I treatment with safety and near- and medium-term efficacy. The Department of Ultrasound Medicine of China-Japan Friendship Hospital has accumulated rich experience in the ablation treatment of benign and malignant thyroid nodules and hyperthyroidism, and has completed more than 200 cases of thyroid ablation in the past two years. Under the leadership of Professor Zhang Bo, the research team of this project has conducted a number of clinical studies on the ultrasound diagnosis and treatment of thyroid diseases, presided over and participated in more than 20 national, provincial and university-level scientific research courses, and the first author or corresponding author wrote more than 70 articles in related fields, which laid a solid research foundation for the conduct of this study. conditions: Hyperthyroidism/Thyrotoxicosis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Ablation therapy measure: Discontinuation rate measure: Recurrence rate sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: China-Japan friendship hospital city: Beijing state: Beijing zip: 100000 country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06305858 id: UKA - PFJ briefTitle: Partial Versus Total Knee Replacement in Bicompartmental Gonarthrosis (Medial and Patellofemoral): Prospective Functional Assessment Study overallStatus: RECRUITING date: 2022-03-01 date: 2025-09 date: 2025-12 date: 2024-03-12 date: 2024-03-12 name: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio class: OTHER briefSummary: The study is, in accordance with current legislation, definable as a prospective single-center interventional randomized study.
24 patients Group B control group: total denture surgical procedure with patellar resurfacing conditions: Knee Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 48 type: ESTIMATED name: Prosthetic Surgical Procedure measure: Assess the difference in score of the KSS (Knee Society Score) questionnaire, completed by the patient in group A compared to the patient in group B sex: ALL minimumAge: 40 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Istituto Clinico San Siro status: RECRUITING city: Milan country: Italy name: Elena Cittera role: CONTACT phone: 0283502224 email: elena.cittera@grupposandonato.it name: Andrea Parente role: PRINCIPAL_INVESTIGATOR lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06305845 id: 152012023 briefTitle: Digital Crowns Versus Prefabricated Crowns on Primary Teeth overallStatus: ACTIVE_NOT_RECRUITING date: 2023-06-01 date: 2023-09-20 date: 2024-09 date: 2024-03-12 date: 2024-03-12 name: National Research Centre, Egypt class: OTHER briefSummary: Badly decayed primary molars will be treated by performing the pulp therapy technique indicated, then the patients will be randomized into two groups to receive the restorative intervention. For the intervention group, teeth will be prepared to receive the digital crown after intraoral scanning while for the control group, teeth will be prepared to receive the prefabricated zirconia crowns. Teeth will be followed up clinically for 1 year, at 1, 6 and 12 months. conditions: Dental Caries in Children studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: a randomized clinical trial with two parallel arms primaryPurpose: TREATMENT masking: SINGLE maskingDescription: participants will not be informed of which crown they will receive whoMasked: PARTICIPANT count: 58 type: ESTIMATED name: Digital crowns measure: Patient and parent satisfaction measure: Crown retention measure: Gingival inflammation measure: Color match sex: ALL minimumAge: 4 Years maximumAge: 10 Years stdAges: CHILD facility: National Research Centre city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06305832 id: IUNU-PC-120 briefTitle: Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer overallStatus: RECRUITING date: 2023-09-07 date: 2028-03 date: 2028-03 date: 2024-03-12 date: 2024-03-12 name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School class: OTHER briefSummary: To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or SRT combination with ADT in prostate cancer patients with biochemical recurrence of prostate-specific antigen(PSA) persistence after radical prostatectomy(RP). conditions: Prostate Cancer conditions: Biochemical Recurrence studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 102 type: ESTIMATED name: Rezvilutamide name: Androgen deprivation therapy (ADT) name: SRT measure: 3-year biochemical progression-free survival measure: progression-free survival (PFS) measure: metastasis-free survival (MFS) measure: percentage of undetectable PSA measure: ctDNA-positive rate measure: ctDNA clearance rate measure: Adverse Events sex: MALE minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University status: RECRUITING city: Nanjing state: Jiangsu zip: 210000 country: China name: Shun Zhang role: CONTACT phone: 15050589789 phoneExt: 15050589789 email: explorershun@126.com lat: 32.06167 lon: 118.77778 facility: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School status: RECRUITING city: Nanjing state: Jiangsu zip: 210000 country: China name: Hongqian Guo, Phd role: CONTACT phone: 13605171690 email: dr.ghq@nju.edu.cn name: Shun Zhang role: CONTACT name: Hongqian Guo role: PRINCIPAL_INVESTIGATOR lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06305819 id: 2023057 briefTitle: Effectiveness of a Self-management Program After Traumatic Injury acronym: SEMPO overallStatus: RECRUITING date: 2024-01-01 date: 2030-12-31 date: 2030-12-31 date: 2024-03-12 date: 2024-04-12 name: Oslo University Hospital class: OTHER name: South-Eastern Norway Regional Health Authority name: Sunnaas Rehabilitation Hospital name: University of Oslo briefSummary: Traumatic injuries, defined as a physical injury with sudden onset, are a leading cause to disability and impaired health. Persons who sustain a traumatic injury often report problems in daily life activities and reduced quality of life, which may limit participation in work/studies, leisure activities and family life. Consequently, complex rehabilitation and support is recommended in National Trauma guidelines due to the often long-lasting physical and psychological sequela of the injury.
The main goal of this study is to determine the effectiveness of a self-management support program delivered to persons with a moderate or severe traumatic injury in the sub-acute phase of recovery (i.e. 3-4 months after injury). The self-management program aims to enhance patients' self-efficacy by building skills and self-management strategies to cope with injury-related consequences. The program has a group-based format and consists of eight sessions comprising psychoeducation, skill mastery and sharing of experiences. The participants who will be included in the study must be between 18 and 70 years, be residing in the southeast region of Norway, be admitted to Oslo University hospital or transferred from local hospital within 72 hours after injury, have at least a two-day hospital stay, and be able to read and understand Norwegian language. Participants will be randomly assigned to either intervention or control group. A group of patients will also be able to self-select if they want to receive the self-management support program or be in the control group. The latter is an explorative part of the study to evaluate the influence of patients' treatment-preferences on the study outcomes. Participants in the control group will receive treatment as usual. conditions: Trauma Injury conditions: Trauma, Multiple conditions: Polytrauma studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 220 type: ESTIMATED name: self-management support program name: Control group measure: Trauma Coping Self-Efficacy measure: Rivermead Post-Concussion Symptom Questionnaire measure: Fatigue Severity Scale measure: Insomnia Severity Index measure: Brief Pain Inventory -short form measure: International Physical Activity Questionnaire measure: Cognitive Failures Questionnaire measure: Patient Health Questionnaire-9 measure: Generalised Anxiety Disorder-7 measure: Impact of Event Scale - Revised measure: Return to work measure: Resilience Scale for Adults measure: EuroQol five-dimensional questionnaire measure: Target Outcomes measure: Patient Global Impression of Change measure: Intervention acceptability and satisfaction measure: Intervention satisfaction measure: WHO Disability Assessment Scale measure: Glasgow Outcome Scale - Extended measure: Communication with physicians measure: Health Literacy Questionnaire measure: Received health care services sex: ALL minimumAge: 18 Years maximumAge: 72 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Oslo University Hospital status: RECRUITING city: Oslo country: Norway name: Mari Storli Rasmussen, PhD role: CONTACT phone: +4799797575 email: masras@ous-hf.no name: Solveig L. Hauger, PhD role: CONTACT phone: +4791310358 email: solveig.hauger@gmail.com lat: 59.91273 lon: 10.74609 hasResults: False
nctId: NCT06305806 id: Pro00112597_B id: OTA-21-015G type: OTHER domain: NIH Grant to RTI; RTI subcontracting with DCRI briefTitle: RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) overallStatus: ENROLLING_BY_INVITATION date: 2024-03-11 date: 2025-12 date: 2026-03 date: 2024-03-12 date: 2024-04-09 name: Kanecia Obie Zimmerman class: OTHER briefSummary: This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans.
This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (POTS), in PASC participants. The interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs. conditions: Long COVID conditions: Long Covid19 conditions: Long Covid-19 studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: In each Appendix trial, each participant will be assigned with equal probability to one of the factorial combinations based on two factors: (1) a study intervention/control and (2) non-pharmacologic intervention/control if the participant is eligible for the study intervention. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Double blind whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 180 type: ESTIMATED name: Ivabradine name: Ivabradine Placebo name: Coordinated Care name: Usual Care measure: Change in Orthostatic Hypotension Questionnaire (OHQ)/Orthostatic Intolerance Questionnaire (OIQ) Composite Score measure: Change in Composite Autonomic Symptoms Score 31 (COMPASS-31) measure: Change in Malmo POTS Symptom Score measure: Change in Active Stand Test measure: Change in blood pressure (BP) measure: Change in heart rate (HR) measure: Change in 6-min Walk Test measure: Change in PROMIS-29 + 2 Questionnaire measure: Change in step count as measured by a wearable device measure: Change in heart rate as measured by a wearable device measure: Proportion of participants who experience individual SAEs measure: Proportion who experience any one or more SAEs measure: Incidence of SAEs leading to discontinuation measure: Incidence of Events of Special Interest (ESIs) measure: Changes in Autonomic Function Testing measure: Change in Vanderbilt Orthostatic Symptoms Score (VOSS) measure: Change in PASC Symptom Questionnaire sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: All sites listed under NCT06305780 city: Durham state: North Carolina zip: 27710 country: United States lat: 35.99403 lon: -78.89862 hasResults: False
nctId: NCT06305793 id: Pro00112597_A id: OTA-21-015G type: OTHER domain: NIH Grant to RTI; RTI subcontracting with DCRI briefTitle: RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG) overallStatus: ENROLLING_BY_INVITATION date: 2024-03-11 date: 2025-12 date: 2026-03 date: 2024-03-12 date: 2024-04-08 name: Kanecia Obie Zimmerman class: OTHER briefSummary: This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans.
This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (POTS), in Post-Acute Sequelae of SARS-CoV-2 infection (PASC) participants. The interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs. conditions: Long COVID conditions: Long Coronavirus Disease 2019 (Covid19) conditions: Long Covid-19 studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: In each Appendix trial, each participant will be assigned with equal probability to one of the factorial combinations based on two factors: (1) a study intervention/control and (2) non-pharmacologic intervention/control if the participant is eligible for the study intervention. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Double blind whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 200 type: ESTIMATED name: IVIG (intravenous immunoglobulin) name: IVIG Placebo name: Coordinated Care name: Usual Care measure: Change in Orthostatic Hypotension Questionnaire (OHQ)/Orthostatic Intolerance Questionnaire (OIQ) Composite Score measure: Change in Composite Autonomic Symptoms Score 31 (COMPASS-31) measure: Change in Malmo POTS Symptom Score measure: Change in Active Stand Test measure: Change in blood pressure measure: Change in heart rate (HR) measure: Change in 6-min Walk Test measure: Change in Patient-Reported Outcomes Measurement Information System (PROMIS-29) + 2 Questionnaire measure: Change in step count as measured by a wearable device measure: Change in heart rate as measured by a wearable device measure: Proportion of participants who experience individual (SAEs measure: Proportion who experience any one or more ( Serious Adverse Event) SAEs measure: Incidence of SAEs leading to discontinuation measure: Incidence of Events of Special Interest (ESIs) measure: Changes in Autonomic Function Testing measure: Change in Vanderbilt Orthostatic Symptoms Score (VOSS) measure: Change in PASC Symptom Questionnaire sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: All sites listed under NCT06305780 city: Durham state: North Carolina zip: 27710 country: United States lat: 35.99403 lon: -78.89862 hasResults: False